Profile: Belinda Guo, PhD, University of Western Australia One of the impacts MPN research Foundation (MPNRF) has on the global MPN community is the support of young investigators who often bring new ideas and approaches to the study of MPNs. That was true of Dr. Belinda Guo when she received her first funding from us… Read More »Belinda Guo
Today, it is essential for patients to be involved with research and drug developers as they progress through the various stages of bringing a new therapy to market. MPN Research Foundation (MPNRF) is committed to ensuring that patient participation is more than a ticked box for drug approval. We actively work to incorporate the patient… Read More »Patients and Caregivers Play an Active Role in MPN Research
Several studies have confirmed the association of ruxolitinib (a JAK inhibitor) with increased risk of non-melanoma skin cancers (NMSCs). A study published in a January 2024 issue of the journal Blood reports on just how serious the risks might be, specifically among patients living with essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF). And… Read More »UK Study Details Skin Cancer Risks for MPN Patients
Jyoti Nangalia, MBBS, PhDWellcome Sanger Institute It is known that JAK2 mutations are found in “healthy” people around the world, particularly in older individuals. Most of them don’t acquire characteristics of myeloproliferative neoplasms (MPNs). The question is why do some people with the mutation develop an MPN while others don’t. Researchers from the Wellcome… Read More »Understanding who develops which MPN and why
Cancer is such a powerful word that it is often referred to as “The Big C” and comes with a loaded associated vocabulary, including words that can have both empowering or disturbing triggers, depending on the individual hearing it. Not many people go through life without being touched by cancer in some way. This means… Read More »Cancer words matter
While cardiovascular events often accompany MPNs and contribute significantly to morbidity and mortality, the reasons remained unclear until research offered some insight in recent years. Greater understanding about why and how blood cancers have connections to cardiovascular complications lays the groundwork to using this information to better assess and manage risk factors in MPN patients,… Read More »Cardiovascular Risk and MPNs
Thrive Award Spotlight: John Crispino, St. Jude Children’s Research HospitalCo-PI – Ayalew Tefferi, Mayo Clinic, MN Aberrant Megakaryopoiesis in the MPNs According to Leukemia & Lymphoma Society, although MPN patients can be stable for decades, they face a significant risk of having their disease advance to a more immediately life-threatening blood cancer, acute myeloid leukemia… Read More »How MPNs progress to AML and how to stop it
Shannon Elf, PhD, University of Utah Huntsman Cancer Institute The metabolic landscape of MPNs is an extremely understudied area in the field. Solid tumor treatment has benefited tremendously from studying cellular metabolism in a number of cancers, and Dr. Shannon Elf, a junior investigator at University of Chicago, believes the same can be… Read More »Learning More About MPN Cell Metabolism to Help Identify Novel Points of MPN Therapy
The world of myeloproliferative neoplasms (MPNs) has witnessed a surge in scientific breakthroughs. From detecting genetic drivers as early as in the fetus to the unprecedented pace of new drug approvals, the momentum is changing how this family of blood cancers is understood and managed. Increased attention and industry investment have led to a growing number of treatment… Read More »What’s Next?
